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ABSTRACT
In this study, two sets of methyl-coated non-porous and mesoporous amorphous silica materials
of two target sizes (100 and 300nm; 10–844m2/g) were used to investigate the potential role of
specific surface area (SSA) and porosity on the oral toxicity in mice. Female Swiss mice were
administered by oral gavage for 5 consecutive days. Two silica dose levels (100 and 1000mg/kg
b.w.) were tested for all four materials. All dispersions were characterized by transmission elec-
tron microscopy (TEM) and Nanoparticle tracking analysis (NTA). Batch dispersions of porous sil-
ica were rather unstable due to agglomeration. Animals were sacrificed one day after the last
administration or after a three-week recovery period. No relevant toxicological effects were
induced by any of the silica materials tested, as evaluated by body weight, gross pathology,
relative organ weights (liver, spleen, kidneys), hematology, blood biochemistry, genotoxicity
(Comet assay in jejunum cells and micronucleus test in peripheral blood erythrocytes), liver and
small intestine histopathology, and intestinal inflammation. The presence of silica particles in
the intestine was evaluated by a hyperspectral imaging microscopy system (CytoViva) using
histological samples of jejunum tissue. Silica spectral signatures were found in jejunum samples
with all the treatments, but only statistically significant in one of the treatment groups.
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1. Introduction
Synthetic amorphous silica nanomaterials are pro-
duced at a level of million tons and are among the
most produced nanomaterials worldwide
(Liljenstr€om, Lazarevic, and Finnveden 2013). They
are broadly used in different industrial sectors, such
as food, electronics, construction, and medicine,
and a large proportion (>10%) of consumer nano-
based products contain silica nanomaterials (Vance
et al. 2015).
Synthetic amorphous silica (SAS) is widely used
as an anti-caking agent (E551) in the food industry
(OECD 2014). SAS consists of mainly micro-sized
aggregates of nano-sized primary particles (Dekkers
et al. 2013). The consumer intake of SAS from food
has been estimated to be around 1.8mg/kg body
weight/day (Dekkers et al. 2011).
Murugadoss et al. (2017) reviewed in vitro and
in vivo toxicological studies on 7–1000 nm-size SAS
materials. In general, for the oral route, only minor
or absence of toxicological findings were observed
in this review, even at very high doses (1–2.5 g/kg
bw/day). No histopathological alterations in the
intestine (Yoshida et al. 2014; Li et al. 2015;
Tarantini et al. 2015) nor in other organs were
reported after gastro-intestinal exposure to SAS
(Kim et al. 2014). One study reported a small
increase in villus heights and crypt depths in
jejunum for several types of SAS (van der Zande
et al. 2014), but later analyses have attributed these
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differences to slightly different orientation of the
histological sections in the controls versus treated
groups (Morfeld et al. 2017).
Liang et al. (2018) reported no treatment-related
local or systemic alterations in a rat oral gavage
subchronic study following the OECD Test Guideline
(TG) 408 with SAS (25.9 ± 3.4 nm) at doses up to
1500mg/kg b.w. In contrast, other studies did
report adverse effects. Tassinari et al. (2020), con-
duced another 90-day repeated dose oral toxicity
study (also following OECD TG 408) with the SAS
NM-203 (13–45 nm). They reported histological
alterations on the liver and spleen, and in blood
thyroid stimulating hormone and creatinine levels.
Histological alterations in the liver and the kidneys
were observed in a 18-month chronic exposure of
the SAS NM-200 (14–23 nm) in mice via drinking
water at 4.8mg/kg bw/day (Boudard et al. 2019).
Chen et al. (2018) reported adverse effects in mice
orally exposed for 7 days to 2.5mg/kg b.w./day SiO2
NP (10.8 ± 1.7 nm, crystallinity not reported), by
evaluating parameters that are not amongst clas-
sical endpoints in OECD test guidelines. In particu-
lar, they found increased pro-inflammatory cytokine
levels in colons of exposed mice as well as
increased microbial species richness and diversity
within the intestinal tract.
Silica can be synthesized with controlled size,
shape, crystallinity, morphology and porosity,
and several of these parameters, as well as the
route of synthesis, have been shown to modu-
late in vitro and/or in vivo biodistribution pat-
terns and toxicity (Murugadoss et al. 2017).
Given the diversity in the type of silica that can
be generated, the existing studies only cover a
few types of silica and are not yet sufficient to
understand how these different properties affect
their toxicity.
Some studies have shown that the porosity of sil-
ica affects cell uptake and toxicity (Lin and Haynes
2010; Maurer-Jones, Lin, and Haynes 2010; Tao et al.
2009; Kettiger et al. 2015; Yu et al. 2012). Most of
the evidence derives from in vitro studies and stud-
ies evaluating the effects after in vivo exposure are
scarce. An intravenous injection study showed a
markedly higher toxicity of porous vs. non-porous
silica particles. In this case, however, toxicity
seemed to be strongly determined by the degree of
aggregation. The porous particles led to larger
aggregates (based on hydrodynamic sizes) and had
a higher potency to induce vascular congestion and
consequently lower maximum tolerated dose (Yu
et al. 2012). The second study evaluated the toxicity
of non-porous (SSA: 27m2/g) and porous SAS (SSA:
495m2/g and 1027m2/g) after a single-dose intra-
venous administration in mice, and did not find
histopathological alterations in liver, lung, spleen, or
kidney (Hadipour Moghaddam, Mohammadpour,
and Ghandehari 2019).
The main focus of this study was to evaluate the
role of SSA on particle toxicity by using four
methyl-coated SAS in a short-term (5-day) repeated
oral administration (STOS) in Swiss female mice, fol-
lowed by a three-week recovery period. Particles
varying in size and in porosity were included to
account for the main factors affecting particle SSA.
Two (non-porous and porous) of these four materi-
als have particle sizes in the upper range of the EC
nanomaterial definition, while the two other materi-
als (also porous and non-porous) are in the submi-
cron range. The high SSA of the submicron porous
material would also classify it as a nanomaterial.
Smaller particle sizes were not used due to tech-
nical difficulties in the generation, at a sufficient
production yield, of silica powders of these charac-
teristics. All the materials were methyl-coated to
minimize the dissolution into ions (Si4þ) (Juere et al.
2020; Fabjan et al. 2020). The study included some
systemic toxicity evaluations, although it focused
mainly on the evaluation of local effects in the
intestine. The test protocol is inspired by the
increasingly used short-term inhalation study (STIS)
to evaluate toxicity of nanomaterials (Landsiedel
et al. 2014). Indeed, other authors have already
used similar exposure and follow-up periods to
evaluate oral toxicity of nanoparticles (e.g. De Jong
et al. 2019).
2. Materials and methods
2.1. Characterization of test materials
SAS powders of two non-porous and two P6MM
mesoporous methyl-coated amorphous silica
materials with target sizes of 100 and 300 nm
were synthesized at NRCWE (Denmark) using the
St€ober process, and methylated to minimize the
dissolution into ions (Si4þ). A full description of
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the method and characteristics of the test mate-
rials is given elsewhere (Sahlgren et al.
forthcoming).
2.1.1. Particle morphology and primary par-
ticle sizes
Transmission electron microscopy (TEM) was con-
ducted with a Tecnai T20 G2 – LaB6 microscope,
operating at 200 kV and images recorded using a
Bottom mounted Ultrascan 1000xp CCD camera at
30 000–100 000 magnification. TEM samples were
prepared using a grid-on-drop method after dis-
persing test materials in distilled water (5wt.%) by
probe-sonication for about 13min at amplitude of
20% (Branson Digital Sonifier S-450D, Branson
Ultrasonics, Danbury, CT, 13mm model 102 C dis-
rupter horn). Additional TEM characterization was
made on a diluted aliquot of the dispersions used
for hydrodynamic size analysis using a JEM-2100 HT
(JEOL Ltd, Tokyo, Japan) operated at an accelerating
voltage of 200 kV (see Section 2.1.4).
2.1.2. Water-loss and methyl-content
Water-loss and concentration of methyl coating was
determined by coupled thermogravimetry-mass-
spectrometry (TGA-MS) using a STA 449F3 TGA and
QMS D A€eolos MS (Netzsch holding; Gebr€uder-
Netzsch-Strasse, Germany). Adsorbed water was
ascribed to TGA mass-loss occurring between 30
and 100 C. The content of methyl coating was
ascribed to a mass-loss event occurring between
395 and 445 C in 100 nm- and 300 nm-size SAS,
and between 165 and 255 C in porous 100 nm-
and porous 300 nm-size SAS. Mass-losses occurring
above the episodic methylation-loss temperatures
were ascribed to structural water (hydroxyls) and
considered part of the silica material. Based on
these data, the amount of amorphous silica, methy-
lation, and adsorbed water was calculated for
each sample.
2.1.3. Specific surface area
The specific surface areas including porosity were
determined using the Brunnauer–Emmett–Teller
(BET) nitrogen (196 C) gas-adsorption method
(Micromeritics TriStar II volumetric adsorption ana-
lyzer; Micomeritics Instrument Corporation,
Norcross, GA, USA). Before the measurements, the
samples were outgassed for 6 h at 120 C under the
flow of nitrogen gas. The BET equation was used to
calculate the surface area between 0.05 and 0.3
relative pressures (P/Po).
2.1.4. Hydrodynamic size analysis
SAS (100mg/mL) dispersions were made in MilliQ-
filtered water with Carboxymethyl cellulose-Tween80VR
(CMC sodium salt high viscosity) Sigma-Aldrich, St.
Louis, MO, USA; Tween80VR (micellar avg mol wt
79 000, Sigma-Aldrich, St. Louis, MO, USA), at 0.2%
(w/v) and 1% (v/v), respectively). Dispersions were
achieved by probe sonication using a Labsonic soni-
cator (VCX750 Ultrasonic Cell Disrupter, VibracellTM,
SONICS(R) NewTown, CT, USA). The sonication proto-
col consisted of a 5-minute sonication in continuous
mode at 20% amplitude using a 3mm  80mm tip
(Sigma-Aldrich, St. Louis, MO, USA). Sonication was
repeated if a satisfactory suspension was not
achieved as assessed by visual inspection. The energy
applied during one sonication round was calculated
to be 6.21 J. After sonication, the dispersion was vor-
texed and diluted to 10mg/mL using the CMC-
Tween80VR vehicle.
Nanoparticle tracking analysis (NTA; Nanosight
NS300, Malvern Panalytical, Malvern, UK) was used
to determine the hydrodynamic size of the test
materials dispersed in the CMC-Tween80VR vehicle.
The 10mg/mL stock concentration of each material
was diluted using MilliQ water to around 1 mg/mL.
The particle suspensions were vortexed immediately
before injection into the NTA sample chamber with
sterile syringes and then 30 s measurements were
performed in triplicate at room temperature.
2.2. Animals and in vivo study design
Swiss female mice (RjOrl:SWISS; 20–24 g of body
weight) were obtained from Janvier-Labs (Le
Genest-Saint-Isle, France). Animals were housed in
groups of 4 individuals per cage in the Animal
Facilities of the Barcelona Scientific Park, under a
12:12 h light:dark cycle at 20 ± 2 C and 55± 30%
humidity. Mice had ad libitum access to Protein
Rodent Maintenance Diet (Ref. 831193 Dietex
International Ltd, Witham, UK) and autoclaved
water. Animal work was approved by the Animal
Welfare Committee (Barcelona Scientific
Park, Spain).
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Groups of eight mice per treatment and dose
level were administered by oral gavage once a day
during a period of five consecutive days. The con-
trol group was administered the vehicle (CMC-
Tween80VR ) that was used to prepare the particle
suspensions. The administration volume was 10mL/kg
body weight (b.w.). Particle dispersions were prepared
at 10mg/mL and 100mg/mL as described above to
obtain 100mg/kg b.w. (Low dose; LD) and
1000mg/kg b.w. (high dose; HD), respectively. Two
follow-up periods were selected after the last
administration: 24-h (day 6 of the experiment) or
21 days (day 26 of the experiment; Recovery group).
Two additional groups of 8 animals each were
orally administered with Methyl methanesulfonate
(MMS, Sigma-Aldrich, St. Louis, MO, USA), a DNA
alkylating agent used as a positive control for geno-
toxicity (Comet assay in the intestine). MMS was
administered at 100mg/kg b.w. during 3 consecu-
tive days, at 48 h, 24 h, and 2–3 h prior to each ter-
mination date.
2.3. Toxicological evaluations
Animals were weighed and clinical signs of toxicity
were assessed daily during the dosing period.
During the 3-week recovery period, these evalua-
tions were performed every 2–3 days. Bodyweight
gain was calculated as the percentage relative to
the body weight at the start of the study.
2.3.1. Micronuclei in peripheral blood erythrocytes
At termination (day 6 or day 26 of the experiment),
animals were anesthetized with Isoflurane (3% þ O2
0.8 L/min). One milliliter of whole blood was
extracted by cardiac puncture and placed in a tub
containing 5 mL of Heparin (1000U/mL, Merck,
Darmstadt, Germany). Five microliters of whole hep-
arinized blood was sampled and diluted 1:5 in fetal
bovine serum (FBS, Biowest, Riverside, MO, USA) on
a microscopy slide to form a smear, dried overnight
and fixated in methanol for micronucleus analysis.
The peripheral blood micronuclei (MN) assay was
performed as described before (Lindberg et al.
2012), in accordance with TG 474 (OECD 2016). The
frequencies of micronucleated polychromatic eryth-
rocytes (MNPCEs) and micronucleated normochro-
matic erythrocytes (MNNCEs), in 2000 polychromatic
(PCEs) and normochromatic erythrocytes (NCEs) per
mouse, respectively, were analyzed using an Axio
Imager Z1 fluorescence microscope (Zeiss,
G€ottingen, Germany).
For SAS-treated groups, the frequency of periph-
eral blood MNPCEs was analyzed in animals sacri-
ficed at day 6, whereas the frequency of peripheral
blood MNNCEs was assessed in animals sacrificed
after the recovery period (day 26). In addition, the
frequencies of peripheral blood MNPCEs were ana-
lyzed in the negative control and the positive (MMS)
control groups at both post-administration times.
2.3.2. Hematology, differential white cell count, and
blood biochemistry
Hematological analyses were performed using
150 mL heparinized blood in a hematology analyzer
(Abacus JuniorVet, DiatronVR , Budapest, Hungary).
Additionally, differential leukocyte counting using
Wright-Giemsa modified staining was performed by
visual evaluation using optical microscopy (Leica
DM100VR , Wetzlar, Germany). Incidence of morpho-
logical variations in leukocytes and incidence of
acanthocytes and anisochromia were also recorded.
The remaining blood was centrifuged (10min,
1500 g at 4 C) to separate the plasma fraction and
analyze aspartate transaminase (AST), alanine trans-
aminase (ALT), creatinine, and total protein concen-
tration using an automatic analyzer (Olympus
AU400 analyzer, Tokyo, Japan).
2.3.3. Gross pathology and tissue weight
Immediately after termination, animals were dis-
sected and examined for macroscopic alterations.
The intestinal tract was excised and processed as
described below for histopathology, the Comet
assay, and tumor necrosis factor (TNF-a) levels.
Liver, spleen, and kidneys were harvested and
weighted, and the left lobule of the liver was pre-
served for histopathology (see below). Relative
organ weights were calculated as the percentage
relative to the body weight at the time of sacrifice.
2.3.4. Comet assay in fresh jejunum samples
The Comet assay was performed on fresh jejunum
intestinal cells of 5–6 animals per treatment group.
Immediately after sacrifice, a piece of 6 cm of
jejunum was harvested, intestinal content was gen-
tly removed, rinsed with mincing buffer containing
Hank’s Balanced Salt Solution (HBSS; Caþ2 and
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Mgþ2 free, Lonza, Pontevedra, Spain), 20mM ethyle-
nediaminetetraacetic acid (EDTA; Sigma-Aldrich, St.
Louis, MO, USA) and 10% (v/v) dimethyl sulfoxide
(DMSO; Sigma-Aldrich, St. Louis, MO, USA) at pH ¼
7.5 at 4 C. The tissue was minced, suspended in
ice-cold phosphate-buffered saline (PBS; Lonza,
Pontevedra, Spain), and passed through a 100 mm
pore size nylon cell strainers (Corning, Corning,
NY, USA). The cell suspensions were centrifuged
twice at 1000 rpm at room temperature and the
supernatant was discarded.
The Comet assay was performed in alkaline con-
ditions (pH > 13). Briefly, 7.5 103 cells were resus-
pended in 30 mL molten (37 C) 0.65% of agarose
(LMPA, Sigma-Aldrich, St. Louis, MO, USA). Drops of
7 mL were put onto GelBondVR films (Lonza,
Pontevedra, Spain) and were allowed to solidify for
5min at 4–8 C. The films were immersed in cold
lysis solution (2.5M, NaCl, 100mM EDTA, 10mM
Tris, 1% (v/v) Triton and 10% (v/v) DMSO) overnight
at 4 C. Films were washed with an alkaline solution
(0.3M NaOH, 1mM EDTA, pH > 13, at 4 C) and left
1 h in this solution to allow unwinding, after which
they were transferred to an electrophoresis tank.
Electrophoresis was performed at 4 C during
20min at 300mA (0.7 V/cm). The films were then
washed twice with PBS and once with MilliQ water
at 4 C for neutralizing the effect of the alkaline
solution, and fixed overnight in 100% ethanol solu-
tion and air-dried at room temperature. The films
were then mounted onto glass microscope slides
(SuperFrostVR Plus, VWR, Radnor, PA, USA). DNA was
stained with 10.000 X SYBRVR Green (Sigma-Aldrich,
St. Louis, MO,USA) solution (Tris 10mM, 1mM EDTA
at pH ¼ 8) rinsed with MilliQ water and let air-dry.
The DNA was visualized using a fluorescein filter
in an epifluorescence microscope (E600, Nikon,
Tokyo, Japan) and images captured using a digital
camera (DP72, Olympus, Tokyo, Japan). A semi-
automated software (Comet Assay IV Software v4.2,
Perceptive Instruments Ltd, Bury Saint Edmunds,
UK) was used to calculate the percentage of DNA in
the Comet tail, which was used as a measure of
DNA damage. Around 100 cells per animal, after
exclusion of hedgehogs were evaluated, except in
the case of MMS treated groups, in which the
higher percentage of hedgehogs lead to a lower
number of cells available for evaluation (an average
of 78 per animal).
2.3.5. Histopathological evaluation of jejunum
and liver
Jejunum samples of all the high dose groups at
Day 6, and liver of all the high dose groups at Day
26 were evaluated for histopathology.
Two jejunum sections of 2 cm in length sepa-
rated by 6 cm were dissected. The intestinal content
was gently removed. Intestine and liver were fixed
with formalin solution (10% neutral buffered forma-
lin solution, Sigma-Aldrich, St. Louis, MO, USA).
Samples were dehydrated and embedded in par-
affin using the tissue processor Tissue-Tek VIP 6
(Sakura, Tokyo, Japan) and paraffin blocks were
mounted. From each block, 4 lm representative tis-
sue sections were obtained using a microtome
(RM2255, Leica, Tokyo, Japan) and stained with rou-
tine Hematoxylin and Eosin (H&E) staining using the
Dako Cover Stainer CS 100-10304 (Agilent,
Lexington, MA, USA), and observed in a microscope
(CX43, Olympus, Tokyo, Japan) for histopathological
alterations. Continuous sections to those used for
histopathology were collected and left unstained
for hyperspectral analyses.
2.3.6. TNF-a levels in jejunal mucosa
A section of approximately 5 cm in length was dis-
sected. The intestinal mucosa was removed by gen-
tly scratching the lumen surface, placed into an
Eppendorf tube and immediately frozen by immer-
sion in liquid nitrogen and kept at 80 C.
Prior to analysis, intestinal mucosa was thawed in
cold RIPA buffer (Sigma-Aldrich, St. Louis, MO, USA)
containing complete protease inhibitor (Sigma-
Aldrich, St. Louis, MO, USA). These samples were
homogenized and incubated using an orbital rota-
tor for 30min at 4 C to extract proteins. Samples
were then centrifuged for 5min at 13 000 rpm and
4 C. The supernatant was used to measure protein
concentration with a BCA protein assay kit
(ThermoScientific, Waltham, MA, USA), and TNF-a
levels with a commercial ELISA kit (Bio-Techne,
Devens, MA, USA). Control samples spiked with
known amounts of TNF-a were used to evaluate
the interference of the matrix in the assay. TNF-a
levels were normalized per milligram of tis-
sue protein.
NANOTOXICOLOGY 5
2.3.7. Identification of SAS in jejunum sections by
hyperspectral analysis
The presence of SAS particles in the jejunum sam-
ples was determined by a hyperspectral imaging
microscopy system (CytoViva, Inc, Auburn, AL, USA)
coupled with an Olympus BX43 optical microscope
(Olympus Corporation, Tokyo, Japan). Tissue sam-
ples were prepared as described above for histo-
pathology. The images were captured, processed,
and analyzed with CytoViva ENVI 4.8 software.
SAS particles were identified following an estab-
lished protocol (Roth et al. 2015) with few modifica-
tions. In brief, for each histological preparation,
2 datacubes were captured with the 40 objective
(600 magnification) and 0.25 s exposure time.
Then, the signal from the datacubes was smoothed
with the Savitski-Golay curve fit smoothing algo-
rithm using an 11-bands width, and corrected for
the lamp spectrum profile. Next, for each material,
histological preparations from animals treated with
the highest dose were analyzed to find the pixels-
spectra that met a certain criteria of light spectra
intensity (5000–16 000 units). The spectral profiles
were merged into a reference spectra library (RSL),
specific for each material. To improve specificity,
the datacubes of untreated samples were sub-
tracted from the RSL of each nanomaterial. Finally,
to identify the material spectral signature in the
control and treated samples, each material-specific
filtered-RSL was used along a pixel-spectral match
algorithm (spectra angle mapper (SAM)). The total
tissue area of each datacube was quantified using
the ROI ENVI 4.8 tool. The total matching pixels
within the region of interest (ROI) were scored and
reported as the percentage of matching pixels in
the tissue.
For confirmation, a second approach based on
generating spectral libraries from the SAS stock dis-
persion (as in Ilves et al. 2014; Wen et al. 2012;
Husain et al. 2013) was applied in selected samples.
In this approach, SAS stock dispersions were used
for creating the spectral libraries along with the
SAM classification algorithm to find the localization
of matching pixels in the histological images.
2.3.8. Microbiome in feces
Fresh feces were collected at day 1, just before the
first administration, and at day 6 of the experiment.
They were placed in ice-cold 20% glycerol (Sigma-
Aldrich, St. Louis, MO, USA) solution in PBS and
kept on ice until storage at 80 C.
Only samples from controls and high dose
groups were analyzed. Four pools of two animals
each were processed per experimental group. After
homogenization, DNA was extracted using the Stool
DNA Isolation Kit (27600, Norgen Biotek, Thorold,
ON, Canada), following the supplier instructions.
The concentration and quality of extracted DNA
were measured through a NanoDrop 2000 C spec-
trophotometer (Thermo Scientific, Waltham, MA,
USA). For metagenomic analysis, fecal samples were
subjected to two-step PCR amplification of the V3-
V4 region of the bacterial 16S ribosomal RNA gene,
using the primers 338 F (50-ACTCCTACGGGAGGCAG
CAG-30) and 806 R (50-GGACTACHVGGGTWTCTAAT
-30) as described elsewhere (Nagpal et al. 2018).
Quality control of the final equimolar-pooled library
was performed using a 2100 Bioanalyzer (Agilent)
and quantified using qPCR. Sequencing was com-
pleted in a MiSeq platform (Illumina), using one
MiSeq 500 cycle flow cell, and according to standard
protocols. A first quality control of sequence data
was performed using the FastQC tool.
For the microbiome analysis, sequencing data
were filtered and quality checked with the plugin-
based microbiome analysis platform QIIME2 2019.4
(https://qiime2.org; Bolyen et al. 2019). The
obtained sequence data were demultiplexed and
quality filtered (q2-demux plugin), obtaining a
median of demultiplexed sequences per sample of
77500. Afterwards, denoising, quality filtering
(median, 8500 sequences) and identification of
sequence variants was done (q2-deblur). Sequences
were clustered (q2 vsearch) at 99% identity and
aligned (q2-alignment) and phylogeny constructed
(fasttree2 and the q2-phylogeny). Alpha diversity
(observed operational taxonomic units – OTUs,
Faith’s Phylogenetic Diversity and Shannon
Diversity) and beta diversity metrics (weighted and
unweighted UniFrac) and principal coordinate ana-
lysis were calculated at a depth of 6000 sequences/
sample (q2-diversity). Sequence variants were taxo-
nomically classified using classify-sklearn against the
Greengenes 13_8 99% OTUs reference sequences.
The artifacts generated with QIIME2 were
imported in R studio with qiime2R package (https://
github.com/jbisanz/qiime2R) for the statistical ana-
lysis and plots generation with RStudio Desktop
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1.2.1335, R v3.6.1 (R Core Team) and libraries: phylo-
seq, microbiome, microbiomeutilities gglot2, vegan,
dplyr, ggpubr, knitr, tibble.
2.4. Statistical analysis
All statistical analyses were performed using Prism
6.02 for Windows (GraphPad Software Inc, La Jolla,
CA, USA), except those for microbiome data, which
were performed using R v3.6.1 (R Core Team). All
results are presented as mean and standard error.
Statistical analysis was based on the recommenda-
tions of the OECD guidance document N 116
(OECD GD 116, 2012). The normality of the data
was evaluated using the Shapiro–Wilk normality
test. For data normally distributed, one-way ANOVA
followed by multiple comparison test followed by
Dunnett’s test was used. Data not following normal
distribution or data consisting of percentages were
analyzed by Kruskal–Wallis ANOVA by ranks test fol-
lowed by Dunn’s posthoc test for multiple group
comparisons. Fisher’s exact test was used to evalu-
ate the incidence of morphological alterations in
blood cells. When comparing only two experimental
groups (negative and positive controls in genotoxic-
ity analyses, and exposed versus non-exposed in
hyperspectral analyses) unpaired Mann–Whitney U-
test was used. For microbiome analyses,
PERMANOVA tests with 999 permutations were
used to determine whether between-groups distan-
ces were significantly different with Weighted and
Unweighted Unifrac. In all cases, groups were con-




Physically, the particles in all samples appeared
spherical to sub-spherical. Some of the mesoporous
silica particles appeared to be partially aggregated
(Supplementary Figure S1). Sahlgren et al. (forth-
coming) have shown that the average Feret-sizes of
the ‘100 nm-size group,’ were 128 nm (non-porous
silica) and 66 nm (porous silica) while they for the
‘300 nm size-group,’ were 301 nm (non-porous silica)
and 224 nm (porous silica). Hence all materials var-
ied around their target sizes.
TGA-MS analysis showed that the four test mate-
rials contained 1.6–2.8wt% methylation and had
0.7–5.9wt% adsorbed water (Supplementary Table
S1). Corrected for adsorbed water content, the silica
material varied between 97.2 and 98.4wt% and
methylation accounted for 1.6–2.8wt%. As
intended, the materials divided into a high (828
and 844m2/g) and a low (10–22m2/g) specific sur-
face area group due to internal and external surface
area, respectively.
3.1.1. Characterization of nanomaterial dispersions
Dispersed in CMC-Tween80VR , TEM micrographs
showed aggregates of different sizes for all the
materials (from a few particles to large aggregates
>1mm; see Supplementary Figure S2), together
with some isolated particles. The hydrodynamic size
of the particle dispersions in CMC-Tween80VR
obtained by NTA was 182 ± 16 nm (100 nm);
173 ± 12 nm (100 nm porous); 322 ± 15 nm (300 nm),
and 316 ± 16 nm (300 nm porous).
3.2. Toxicological evaluations
3.2.1. Clinical signs and body weight
No clinical signs of toxicity were observed during
the study period. No statistically significant differen-
ces in body weight and body weight gain were
found between the different treatments and the
vehicle (Supplementary Table S2).
3.2.2. Gross pathology and organ weights
At sacrifice, no relevant macroscopic abnormalities
were observed. Some statistically significant differ-
ences between groups were observed in spleen
weight (i.e. decrease in the high dose of the
100 nm SAS at day 6, and increase in the high dose
of 300 nm porous SAS at day 26) and in liver weight
(i.e. increase in the high dose of 300 nm porous SAS
at day 26) (Supplementary Table S3).
3.2.3. Hematology, differential white cell count, and
blood biochemistry
Only a few statistically significant differences were
observed in hematology between the control group
and some SAS-treated groups with unclear relation
to the treatment and toxicological significance. At
day 6, the low dose of 300 nm non-porous SAS
showed statistically significant higher mean platelet
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volume (MPV) and higher platelet volume distribu-
tion width (PDWsd (fL) and PDWcv (%)) than the
control group. At Day 26, these differences were
not observed (Supplementary Table S4).
Some statistically significant differences in red
blood cells (RBC) and hemoglobin levels were
observed between the control and some exposed
groups at day 26 (Supplementary Table S4). But
these differences might be due to the particularly
high values in the control group observed at
day 26.
The differential white cell count showed that the
percentage of eosinophils at day 26 for both non-
porous 100 nm and porous 300 nm groups at the
high dose was statistically higher than the control
group (Supplementary Table S4). These differences
may be due to the low percentage of eosinophils
found in the control group at day 26 (0.38%) in
comparison to day 6 (4.75%). Indeed, the animal
supplier states an indicative value of 4.10% of eosi-
nophils in the blood of healthy Swiss female mice.
No qualitative or quantitative differences in terms
of the presence of basophilia, cytoplasmic granula-
tion, or prominent nucleoli were found.
Among the blood biochemistry parameters ana-
lyzed, the only statistically significant difference ver-
sus the control group was a decrease in creatinine
content for the 100 nm low dose group on day 26,
with no toxicological relevance (Supplementary
Table S4).
3.2.4. Histopathological evaluation of jejunum
and liver
All the groups, including control groups at both
time points (day 6 and day 26), presented minor
histopathological findings in the small intestine:
mild cellular infiltrate, necrotic/apoptotic cells, and
vacuolated cells (Supplementary Figure S3), nor-
mally presented in the lamina propria of the intes-
tinal villi. These variations were of low incidence
and severity and were not treatment-related.
No relevant hepatic lesions were present in any
of the samples. Irrespective of the group, including
the control group, a low number of small foci of
mixed inflammatory cell infiltrates with the pres-
ence of isolated necrotic hepatocytes were
observed (Supplementary Figure S4). In some of the
samples, a slight mononuclear inflammatory cell
infiltrate was also observed in portal spaces. These
multifocal inflammatory lesions were considered
background lesions frequently found in mice main-
tained in conventional animal facilities.
Table 1. Frequency of micronucleated cells [MNCs, mean (SD)] in 2000 normochromatic (NCEs) and polychromatic (PCEs) periph-
eral blood erythrocytes of vehicle [0.2% (w/v) CMC þ 1% (v/v) Tween80 in MilliQ water], methylated (Me) non-porous (100 and
300 nm) and methylated porous (100 and 300 nm) SAS-treated and methyl methanesulfonate (MMS)-treated mice.
Time point, tissue Treatment Dose (mg/kg bw/administration) No. of animals MNCs/2000 NCEs MNCs/2000 PCEs % PCEs in 500 erythrocytes
Day 6, peripheral blood
Vehicle control – 8 – 4.38 (2.13) 3.40 (0.70)
100 nm 100 8 – 4.00 (2.00) 3.10 (0.90)
100 nm 1000 7 – 1.57 (2.23) 3.40 (1.20)
100 nm porous 100 8 – 3.50 (1.69) 3.60 (1.20)
100 nm porous 1000 8 – 2.75 (3.11) 4.10 (1.30)
300 nm 100 8 – 2.13 (1.46) 2.80 (0.60)
300 nm 1000 8 – 4.00 (4.38) 3.20 (1.50)
300 nm porous 100 8 – 2.50 (2.51) 3.10 (0.90)
300 nm porous 1000 8 – 2.57 (1.62) 3.40 (0.90)
MMS 100 8 – 37.50 (22.25) 2.70 (1.60)
Day 26, peripheral blood
Vehicle control – 8 4.63 (1.85) 1.63 (0.74) 3.40 (0.90)
100 nm 100 8 3.88 (1.46) – 3.40 (0.80)
100 nm 1000 8 5.38 (2.50) – 4.60 (1.80)
100 nm porous 100 8 5.00 (2.00) – 4.10 (1.70)
100 nm porous 1000 8 5.00 (2.56) – 4.30 (0.90)
300 nm 100 8 4.25 (2.82) – 3.80 (1.10)
300 nm 1000 8 4.00 (1.31) – 4.80 (1.30)
300 nm porous 100 8 3.25 (1.58) – 4.30 (0.50)
300 nm porous 1000 8 4.63 (1.19) – 4.20 (0.80)
MMS 100 8 6.50 (1.31) 23.75 (12.21) 3.80 (1.60)
The proportion (%) of PCEs in 500 erythrocytes was determined to indicate possible toxicity. Samples were collected at day 6 and after a recovery period
at day 26. Asterisks indicate significant differences to the corresponding control (p< 0.01; Mann–Whitney U-test).
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3.2.5. Genotoxicity
No differences compared to the control group in
the frequency of micronucleated (MN) normochro-
matic erythrocytes (NCEs) or polychromatic eryth-
rocytes (PCEs) in peripheral blood at any of the
post-administration times were observed (Table 1).
The frequency of MNNCEs reflects chromosome
damage accumulated from the beginning of the
treatment until about 60 h before the blood sam-
pling, whereas the frequency of MNPCEs assesses
chromosome damage that occurred 36–48 h before
the sampling. For this reason, the frequency of
MNPCEs was assessed for day 6 samples. In all silica
particle treatments, the percentage of PCEs among
blood erythrocytes was similar to the values of the
negative control group, indicating that the particles
did not induce bone marrow toxicity. The positive
control treatment (MMS) increased the frequency of
MNPCEs in peripheral blood by 8.6-fold at day 6
and 14.4-fold at day 26 in comparison with the
negative control. MMS did not, however, affect the
frequency of micronuclei in NCEs of peripheral
blood, as expected due to the shorter treatment.
MMS slightly reduced the percentage of PCEs in











































































































































Figure 1. DNA tail intensity (%) of jejunum samples from animals orally administered the vehicle (CTRL), the positive control
MMS (100mg/kg b.w.) or SAS particles and sacrificed at day 6 (A) or day 26 (B). LD: Low dose (100mg/kg b.w). HD: High dose
(1000mg/kg b.w.). All values are means± SEM (n¼ 6). () p< 0.05, one-way ANOVA followed by Dunnett’s test (SAS exposed











































































































































Figure 2. TNF-a levels in jejunal mucosa from animals orally administered the vehicle (CTRL) or SAS particles and sacrificed at
day 6 (A) or day 26 (B). LD: Low dose (100mg/kg b.w). HD: High dose (1000mg/kg b.w.). All values are means± SEM (n¼ 6). No
statistically significant differences (p< 0.05) were observed by means of one-way ANOVA followed by Dunnett’s test .
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No significant differences were observed in the
percentage of DNA in tail in intestinal cells at day 6
or 26 (Figure 1) between the negative control and
the silica-treated groups. The positive control (MMS)
showed a clear statistically significant increase in
the percentage DNA in tail compared to the nega-
tive control (Figure 1).
3.2.6. Inflammatory markers in jejunal mucosa
There was a trend toward elevated TNF-a levels in
the intestinal mucosa of some SAS-exposed groups
vs. the vehicle control group. However, none of the
values reached statistical significance at any of the
time points evaluated (Figure 2).
3.2.7. Hyperspectral analyses
Example images (histology and hyperspectral) for
animals treated with 100 nm non-porous silica are
presented in Figure 3, and example images for all
remaining experimental groups and controls are
shown in Supplementary material (Supplementary
Figures S7–S11). The percentage of matching pixels
per tissue (number of colored pixels in tissue pixels)
showed high variability for all SAS-treated groups,
and only for non-porous 100 nm SAS a statistically
significant difference when compared to the con-
trols was observed (Figure 4). The localization of
matching pixels from the analysis based on RSL
from the stock particle dispersions was consistent
Figure 3. Microscopy image from a jejunum section of a swiss female mouse treated with 1000mg/kg b.w. 100 nm non-porous
SAS. (B) Magnification of the image (A) white contour square area. (C) Image obtained with hyperspectral imaging microscopy
from the same field of a consecutive jejunum section of image (A). Colored pixels indicate a spectral match with the RSL for
100 nm non-porous SAS. (D) Magnification of the image C white contour square area.
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with the matching pixels in the analysis based on
RSL from intestinal tissue slides of treated animals
(Figure 5).
3.2.8. Microbiome study in feces
A total of 661 different OTUs were detected with
the 99% OTU clustering. The two most abundant
families across the different study groups were S24-
7 and Rikenellaceae (Supplementary Figure S5), both
belonging to the phylum Bacteroidetes. Alpha
diversity analyses showed no differences in the
Shannon diversity index or in the phylogenetic
diversity index amongst the different groups after
6 days of administration. However, there was a
trend toward a reduction on the diversity among all
the groups (including controls) compared to the
values recorded on day 1, reaching statistical signifi-
cance only for some of the groups (Figure 6).
No effect on phylogenetic diversity was
observed, neither based on taxa abundances
(p¼ 0.28; weighted UniFrac), nor for observed taxa
based on incidence (p¼ 0.696; unweighted UniFrac).
Principal coordinate analysis showed no specific
clustering (Supplementary Figure S6).
4. Discussion
No local or systemic toxicity (including genotoxicity)
were observed after short-term oral exposure to nei-
ther 100 or 300nm-size non-porous or mesoporous
SAS up to 1g/kg in mice. The study was mostly
focused on evaluating local toxicity and included
histopathology, evaluation of pro-inflammatory cyto-
kines in the intestinal mucosa, potential induction of
DNA damage in the jejunum epithelial cells, as well
as evaluation of effects on the intestinal microbiome.
The lack of histopathological effects in the intes-
tine are consistent with most previous studies in
rodents investigating oral toxicity of porous (Fu
et al. 2013; Li et al. 2015) or non-porous SAS (Kim
Figure 4. Percentage of matching pixels within the specified the tissue area of control and treated animals. HD: High dose
(1000mg/kg b.w.). All values are meansþ SEM (n¼ 7). Mann–Whitney U-test () p< 0.01.
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et al. 2014; Yun et al. 2015; Yoshida et al. 2014; Kim
et al. 2017; Liang et al. 2018; Tassinari et al. 2020).
Some of the previous studies had included similar
high doses (following the recommendations for
dose selection of the OECD test guidelines) or even
much longer administration periods. Chen et al.
(2018) reported only minor histological effects in
the colon after 7-day oral gavage administration of
11 nm silica in mice.
The study by Chen et al. (2018) reported
increased levels of pro-inflammatory markers,
namely IL-1b, IL-6, and TNF-a, in the colon. Also in
oral toxicity studies for other nanomaterials,
increased levels of proinflammatory markers have
been reported at doses that did not induce histo-
pathological changes (Bettini et al. 2017). Evaluation
of cytokine levels in tissues is challenging due to
the potential interference of the matrix in the quan-
tification Elisa kits. We conducted preliminary
experiments with spiked samples to evaluate recov-
ery and linearity in the response. Although we
attempted to evaluate S100A8/A9 levels, the matrix
affected the robustness of the assay and this test
was finally not included. Assay protocols suggested
by kit suppliers and mostly optimized for the detec-
tion of cytokine levels in serum or cell supernatants
may not be adequate for other types of matrices. It
is unclear in previous publications assessing
Figure 5. Comparison of two material specific reference spectral libraries: obtained from a treated mouse or from the SAS stock
dispersion. The hyperspectral microscopy images correspond to a jejunum section of a mouse treated with 1000mg/kg b.w.
100 nm porous SAS from the follow-up group (26 days). (B) and (C) are magnifications of image (A) white contour square area,
analyzed using a RSL obtained from jejunum sections of a treated mouse (B) or using a RSL obtained from the stock SAS disper-
sion (C).
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cytokine levels in tissues whether such type of con-
trols were evaluated. The assay for TNF-a was
robust when applied to evaluate levels in intestinal
mucosa, but no differences between any of the
treated groups and the control group
were observed.
In our study, neither non-porous or mesoporous
SAS caused any detectable genotoxicity locally in
the jejunum (evaluated by the Comet assay) or sys-
temically (evaluated by the mammalian erythrocyte
micronucleus assay) at the end of the administra-
tion period and after the three-week recovery
period. Kwon, Koedrith, and Seo (2014) and
Tarantini et al. (2015) also reported no genotoxicity
after oral exposure to SAS, but Kwon, Koedrith, and
Seo (2014) focused on other tissues, and Tarantini
et al. (2015) used considerably lower doses. Kwon,
Koedrith, and Seo (2014) administered 20 and
100 nm non-porous SAS three consecutive times by
oral gavage to male rats up to a 2000mg/kg b.w.
and used the Comet assay to evaluate the genotox-
icity in the stomach and the liver. In the same
study, mice were orally administered twice using
the same dose levels and the micronucleus assay
was performed in the bone marrow. In both rodent
species, no genotoxicity was observed. Tarantini
Figure 6. Box-plots illustrating (A) Shannon diversity index and (B) phylogenetic diversity prior to the first administration and at
day 6 for controls and SAS-treated groups. Median values and interquartile ranges have been indicated in the plots.
Kruskal–Wallis pairwise test, () denotes p< 0.05.
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et al. (2015) reported no effects on DNA damage by
the Comet assay in several organs and tissues (duo-
denum, colon, bone marrow, blood, kidney, spleen
and liver) of rats orally administered three times
(48, 24, and 3 hours before sacrifice) with four differ-
ent SAS (primary size from 17.7 to 24.7 nm),
although they only tested doses up to 20mg/
kg b.w.
Genotoxicity of SAS has also been studied by
other administration routes. Intravenous administra-
tion of SAS caused a significant effect at very high
doses. In the study by Downs et al. (2012), SAS
(15 nm and 55 nm; SSA: 200m2/g and 50m2/g)
caused a small, but significant increase in DNA
damage in liver (15 nm SAS) and circulating micro-
nucleated reticulocytes (both 15 and 55 nm SAS)
when intravenously tested at the maximum toler-
ated dose (3 consecutive daily administrations at
50mg/kg b.w., with evaluation 3 hours after the last
administration). The same 15 nm SAS induced no
significant effects in the standard Comet assay in
liver, but induced a statistically significant increase
in liver DNA damage evaluated by the hOGG1
Comet assay, which involves an oxidative damage
probably induced as a consequence of the inflam-
matory response (Pfuhler et al. 2017). In contrast,
Guichard et al. (2015) reported no genotoxicity
(Comet and micronucleus assays) in rats adminis-
tered three consecutive daily intravenous doses of
24.7 nm SAS (SSA: 204m2/g) up to 20mg/kg b.w.
Intratracheal instillation studies have neither shown
genotoxic effects with single (Maser et al. 2015) or
cumulative doses up to 36mg/kg SAS (Guichard
et al. 2015) in the range of 15–55 nm. Our study
adds supporting evidence to the lack of genotoxic-
ity of SAS, consistently with previous oral and intra-
tracheal instillation studies. Internal doses achieved
in the intravenous studies that observed (probably
secondary) genotoxicity are predicted to be much
higher than those reached by oral or intracheal
instillation studies.
The four materials that we investigated in this
study have also been evaluated in an intratracheal
instillation study. In that case, the introduction of
porosity increased the toxicity of silica particles per
mass unit (Hadrup et al. forthcoming).
Beyond local toxicity, one of the main concerns
of insoluble nanoparticle exposure is the potential
systemic absorption and consequent long-term
accumulation. Hyperspectral imaging is a relatively
new technique to assess the presence and distribu-
tion of nanomaterials in biological samples in a
label-free manner, allowing minimal interference
with the sample integrity, which permits its assess-
ment with other methods later. Several studies
using an hyperspectral image system have been
performed to detect different type of metallic,
metal oxides, and even organic NPs in a variety of
tissues (Ilves et al. 2014; Husain et al. 2013; Talamini
et al. 2017; Holian et al. 2019). In some studies,
inductively coupled plasma mass spectrometry
(ICP-MS) has been used to confirm the results of
hyperspectral data (Talamini et al. 2017). In this
case, measuring silicon via ICP-MS would be chal-
lenging due to the ubiquitous presence of silica in
labware and the analytical equipment and the nat-
ural-occurring silicon background in tissues (Aureli
et al. 2020).
In this study, the presence of silica particles in
the jejunum of treated mice was assessed through
a hyperspectral imaging system. Analysis of tissue
samples by hyperspectral is complex due to the
interference of the matrix in the particle scattering
properties (Roth et al. 2015). In addition, in an oral
administration study, the physicochemical proper-
ties of test materials might change along the
gastrointestinal tract and consequently affect the
particle scattering properties (Walczak et al. 2015).
For these reasons, the RSL were generated from the
treated samples. In parallel, RSL generated from the
stock particle dispersions were used in some sam-
ples for confirmation, and consistent localization of
pixels was observed. However, the overall percent-
age of matching pixels was lower when evaluated
using RSL generated from the stock dispersions
than when generated from the exposed tissues,
possibly due to the reasons described above. These
two approaches to generate RSL are the most com-
monly used in previous studies. The results of the
hyperspectral analyses suggest the presence of silica
in intestinal tissue of exposed animals. Statistically
significant differences vs. the control group were only
recorded for the 100nm non-porous SAS group. This
test material corresponds to the smallest particle size
tested and possibly the smallest particle agglomer-
ates, due to an observed higher tendency to agglom-
erate of high-porosity particles. Nevertheless, the
high intra- and inter-individual variability, related to
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the irregular distribution of the different silica par-
ticles in the tissues, may have hindered the detection
of statistically significant differences versus the con-
trols for other groups. Note that the use of material-
specific RSL only allowed comparisons toward
respective control groups, but not across particle-
exposed groups.
No treatment related effects were observed in
the microbiome analyses. Some significant differen-
ces were found when comparing feces collected on
day 6 versus those on day 1 of the study, in the
Shannon (100 nm SAS) and phylogenetic (300 nm
SAS) diversity indexes. Such effects are likely to be
related to the vehicle rather than the test material,
as no statistically significant differences between
control and treated groups at day 6 were recorded.
We only identified another study (Chen et al.
2018) evaluating effects on microbiota after oral
administration of silica nanomaterials. They adminis-
tered 11 nm silica to mice for seven days and
reported an increase in microbial species richness
and diversity. In our study, much higher doses did
not lead to significant effects. The differences
between these two studies might be related to the
considerably larger particle sizes and surface methy-
lation of silica particles in our study, but also the
fact that potential effects associated to the vehicle
(explaining differences between in diversity indexes
day 1 and day 6 of the study) might have masked
particle-related effects in our study.
One of the main goals of the study was to inves-
tigate the role of meso-porosity-driven high specific
surface area in the oral toxicity of SAS. Owing to
the lack of test-item related adverse responses in all
the parameters evaluated, it is concluded that none
of the tested non-porous and high porosity SAS
materials induced adverse effects. The clear differ-
ences that were observed in primary particle char-
acteristics, dispersibility and handling of these
four silica dispersions (i.e. high propensity to
aggregation of the porous particles) did not trans-
late into different biological responses. It should
be noted that the sizes of the particles tested
ranged from the upper limit or above the regula-
tory size-definition of nanomaterials and the aim
was to investigate the role of specific surface area
in this scenario. It should also be noted that the
SAS particles were methylated to minimize dissol-
ution of Si4þ ions, whereas such coating is, to our
knowledge, not used in food grade silica. Smaller-
size and uncoated silica particles, as tested in
some previous studies may show a different pat-
tern of effects.
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